Description
First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML
Article: First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML
€3.03
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart
Reviews
There are no reviews yet.